Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer

Yuzhu Hu; Ting Yu; Xiaoxiao Liu; Yihong He; Lihong Deng; Jiajuan Guo; Yuanqi Hua; Ting Luo; Xiang Gao

doi:10.18632/oncotarget.23507

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2020; 11:3484-3485.

Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer

Yuzhu Hu, Ting Yu, Xiaoxiao Liu, Yihong He, Lihong Deng, Jiajuan Guo, Yuanqi Hua, Ting Luo and Xiang Gao _

PDF | HTML | How to cite

Oncotarget. 2018; 9:2515-2526. https://doi.org/10.18632/oncotarget.23507

Metrics: PDF 2232 views | HTML 2346 views | ?

Abstract

Yuzhu Hu1, Ting Yu1, Xiaoxiao Liu1, Yihong He1, Lihong Deng1, Jiajuan Guo1, Yuanqi Hua1, Ting Luo1 and Xiang Gao2

1Department of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China

2Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China

Correspondence to:

Xiang Gao, email: [email protected]

Ting Luo, email: [email protected]

Keywords: colorectal cancer; oxaliplatin; fibrin glue; anti-tumor activity; cell proliferation

Received: October 17, 2017 Accepted: December 05, 2017 Published: December 20, 2017

ABSTRACT

Colorectal cancer is very common worldwide and advanced colorectal cancer exhibited very poor clinical outcome. Oxaliplatin (OXP) is one of the principal chemotherapeutic agents in colorectal cancer treatment presenting impressive anti-tumor ability, limited by adverse effect in clinical practice. Fibrin glue (FG) is a biocompatible formulation made of fibrinogen and thrombin, extensively used in surgery for hemostasis, tissue adhesion and sealing. In this study, FG was innovatively applied as OXP delivery system and results showed enhanced anti-tumor performance in subcutaneous model and abdominal metastasis model of murine colorectal cancer compared with that of OXP used alone. It is revealed that combination of OXP and FG could increase activated CD8⁺ T cells, reduce regulatory T (Treg) cells and increase interferon-γ (IFN-γ). Furthermore, results showed promoted tumor apoptosis, decreased proliferation and inhibited tumor angiogenesis by OXP and FG combination. No obvious systemic toxicity was observed in this study. Finally, our findings provided basis for promising application of OXP and FG combination in colorectal cancer treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23507

Publication Alerts

Research Papers:

Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer

Abstract